Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Key RCC data: JAVELIN Renal 101 & CheckMate 214

Pavlos Msaouel • 13 Feb 2020
GU Cancers 2020
Genitourinary Cancer Kidney Cancer Sitravatinib
CheckMate 214 JAVELIN Renal 101

Pavlos Msaouel, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, gives his opinion on the key kidney cancer data to be taken away from this meeting. Dr Msaouel highlights the JAVELIN Renal 101 (NCT02684006) and CheckMate 214 (NCT02231749) trials, as well as new therapies. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Pavlos Msaouel

1:59
Key objectives in kidney cancer: treatment sequencing & refining clinical endpoints
Pavlos Msaouel • 3 Jun 2022
2:50
Sitravatinib and nivolumab in ccRCC following progression on antiangiogenic therapy
Pavlos Msaouel • 3 Jun 2022
1:11
Current standard of adjuvant therapy in kidney cancer
Pavlos Msaouel • 3 Jun 2022
2:35
Adjuvant therapy in RCC: harnessing prognostic information
Pavlos Msaouel • 3 Jun 2022

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals